Pharmacosmos investigates anemia treatment in new patient group

A new phase III study will shed light on the efficacy of Pharmacosmos's Monoferric/Monofer in children and adolescents. This patient segment has not been eligible for the iron deficiency anemia treatment before.

Photo: Pharmacosmos / PR

Danish Pharmacosmos is on the hunt for 200 patients between the ages 0 and 18 for a clinical phase III trial involving intravenous injection treatment Monoferric, also known as Monofer, for iron deficiency anemia (IDA).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs